HK Stock MarketDetailed Quotes

03347 TIGERMED

Watchlist

32.300
-1.700-5.00%

Trading Nov 22 15:43 CST

27.94BMarket Cap26.24P/E (TTM)

TIGERMED Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q9)Sep 30, 2024

(Q6)Jun 30, 2024

(Q3)Mar 31, 2024

(FY)Dec 31, 2023

(Q9)Sep 30, 2023

(Q6)Jun 30, 2023

(Q3)Mar 31, 2023

(FY)Dec 31, 2022

(Q9)Sep 30, 2022

(Q6)Jun 30, 2022

Turnover

-10.32%5.07B

-9.50%3.36B

-8.00%1.66B

4.21%7.38B

4.52%5.65B

3.25%3.71B

-0.73%1.8B

35.91%7.09B

59.23%5.41B

74.78%3.59B

Operating income

-10.32%5.07B

-9.50%3.36B

-8.00%1.66B

4.21%7.38B

4.52%5.65B

3.25%3.71B

-0.73%1.8B

35.91%7.09B

59.23%5.41B

74.78%3.59B

Cost of sales

----

-6.12%-4.56B

----

-45.01%-4.3B

----

-99.72%-2.18B

Operating expenses

8.12%-3.1B

9.17%-2.03B

5.23%-1.03B

-6.12%-4.56B

-4.12%-3.37B

-2.48%-2.23B

2.06%-1.09B

-45.01%-4.3B

-79.13%-3.24B

-99.72%-2.18B

Gross profit

-13.57%1.97B

-10.00%1.33B

-12.21%628.12M

1.26%2.82B

5.12%2.28B

4.42%1.48B

1.37%715.52M

23.90%2.79B

36.58%2.17B

46.69%1.42B

Selling expenses

-9.22%-144.94M

-13.91%-101.38M

-3.43%-46.45M

-24.97%-187.32M

-22.94%-132.7M

-11.19%-89M

-16.61%-44.91M

-15.84%-149.89M

-12.61%-107.94M

-20.08%-80.04M

Administrative expenses

-5.85%-558.43M

-8.70%-376.62M

-3.60%-177.07M

-3.01%-662.7M

-14.39%-527.54M

-7.81%-346.47M

-7.54%-170.92M

-15.95%-643.32M

-18.67%-461.2M

-30.28%-321.38M

Research and development expenses

11.90%-172.1M

2.65%-124.69M

0.95%-63.91M

-11.48%-261.56M

-14.20%-195.34M

-15.89%-128.08M

-13.22%-64.52M

-10.76%-234.62M

-10.50%-171.06M

-18.80%-110.52M

Profit from asset sales

5,815.94%2.67M

25,346.07%1.49M

32,651.46%1.15M

----

282.55%45.22K

---5.9K

41.47%-3.54K

----

95.63%-24.77K

----

Revaluation surplus

-104.84%-34.41M

-118.58%-98.4M

-92.77%12.75M

----

76.46%710.39M

--529.76M

40.98%176.41M

----

-63.97%402.59M

----

-Changes in the fair value of other assets

-104.84%-34.41M

-118.58%-98.4M

-92.77%12.75M

----

76.46%710.39M

--529.76M

40.98%176.41M

----

-63.97%402.59M

----

Impairment and provision

-21.51%-55.1M

-21.18%-36.08M

11.22%-18.4M

-177.10%-68.1M

-0.74%-45.34M

-4.81%-29.78M

-76.90%-20.73M

-0.61%-24.58M

-152.89%-45.01M

-177.13%-28.41M

-Other impairment is provision

-21.51%-55.1M

-21.18%-36.08M

11.22%-18.4M

-177.10%-68.1M

-0.74%-45.34M

-4.81%-29.78M

-76.90%-20.73M

-0.61%-24.58M

-152.89%-45.01M

-177.13%-28.41M

Special items of operating profit

-5.47%130.76M

-18.28%88.09M

-61.93%11.78M

-4.57%863.91M

25.78%138.34M

-81.95%107.8M

-50.70%30.94M

-61.84%905.28M

-17.65%109.98M

-48.26%597.37M

Operating profit

-49.39%1.12B

-55.58%670.96M

-44.66%340.28M

-5.06%2.5B

17.21%2.21B

2.38%1.51B

-1.46%614.94M

-28.70%2.64B

-13.08%1.88B

-13.47%1.48B

Financing cost

-129.66%-31.37M

-81.71%16.11M

37.34%21.92M

-44.14%-119.9M

-11.06%105.76M

383.86%88.09M

-47.37%15.96M

-233.92%-83.18M

-32.28%118.91M

-290.77%-31.04M

Share of profits of associates

----

164.52%105.18M

----

177.13%39.76M

----

4,817.84%35.56M

Special items of earning before tax

-24.63%2.07M

452.48%3.02M

2.21%167.98K

----

-45.03%2.75M

--547.3K

-89.86%164.35K

----

201.12%4.99M

----

Earning before tax

-53.03%1.09B

-56.85%690.09M

-42.58%362.36M

-4.04%2.49B

15.38%2.31B

8.06%1.6B

-3.80%631.06M

-29.67%2.59B

-14.12%2.01B

-12.83%1.48B

Tax

35.83%-183.93M

30.64%-132.51M

20.63%-49.79M

-7.96%-338.61M

-22.61%-286.62M

-17.76%-191.06M

23.52%-62.74M

-7.10%-313.65M

-55.66%-233.77M

-56.70%-162.24M

After-tax profit from continuing operations

-55.46%903.14M

-60.40%557.58M

-45.00%312.57M

-5.68%2.15B

14.42%2.03B

6.87%1.41B

-0.98%568.33M

-32.84%2.28B

-18.92%1.77B

-17.35%1.32B

Earning after tax

-55.46%903.14M

-60.40%557.58M

-45.00%312.57M

-5.68%2.15B

14.42%2.03B

6.87%1.41B

-0.98%568.33M

-32.84%2.28B

-18.92%1.77B

-17.35%1.32B

Minority profit

-39.49%89.71M

227.70%64.73M

59,975.46%77.5M

-52.83%125.08M

-11.54%148.24M

-84.28%19.75M

-100.23%-129.43K

-48.76%265.17M

-58.59%167.58M

-62.42%125.62M

Profit attributable to shareholders

-56.72%813.43M

-64.50%492.85M

-58.65%235.07M

0.52%2.03B

17.13%1.88B

16.47%1.39B

9.65%568.46M

-29.98%2.02B

-9.90%1.6B

-5.39%1.19B

Basic earnings per share

-56.68%0.94

-64.60%0.57

-59.09%0.27

0.43%2.34

16.67%2.17

16.67%1.61

10.00%0.66

-29.82%2.33

-9.27%1.86

-4.83%1.38

Diluted earnings per share

-56.68%0.94

-64.60%0.57

-59.09%0.27

0.43%2.34

16.67%2.17

16.67%1.61

10.00%0.66

-29.61%2.33

-8.82%1.86

-4.17%1.38

Currency Unit

CNY

Accounting Standards

CAS (2007)

IAS

CAS (2007)

IAS

CAS (2007)

IAS

Audit Opinions

Unqualified Opinion

Auditor

Lixin Certified Public Accountants (Special General Partnership), Hong Kong Lixin Dehao Certified Public Accountants Limited

	(Q9)Sep 30, 2024	(Q6)Jun 30, 2024	(Q3)Mar 31, 2024	(FY)Dec 31, 2023	(Q9)Sep 30, 2023	(Q6)Jun 30, 2023	(Q3)Mar 31, 2023	(FY)Dec 31, 2022	(Q9)Sep 30, 2022	(Q6)Jun 30, 2022
Turnover	-10.32%5.07B	-9.50%3.36B	-8.00%1.66B	4.21%7.38B	4.52%5.65B	3.25%3.71B	-0.73%1.8B	35.91%7.09B	59.23%5.41B	74.78%3.59B
Operating income	-10.32%5.07B	-9.50%3.36B	-8.00%1.66B	4.21%7.38B	4.52%5.65B	3.25%3.71B	-0.73%1.8B	35.91%7.09B	59.23%5.41B	74.78%3.59B
Cost of sales	----	----	----	-6.12%-4.56B	----	----	----	-45.01%-4.3B	----	-99.72%-2.18B
Operating expenses	8.12%-3.1B	9.17%-2.03B	5.23%-1.03B	-6.12%-4.56B	-4.12%-3.37B	-2.48%-2.23B	2.06%-1.09B	-45.01%-4.3B	-79.13%-3.24B	-99.72%-2.18B
Gross profit	-13.57%1.97B	-10.00%1.33B	-12.21%628.12M	1.26%2.82B	5.12%2.28B	4.42%1.48B	1.37%715.52M	23.90%2.79B	36.58%2.17B	46.69%1.42B
Selling expenses	-9.22%-144.94M	-13.91%-101.38M	-3.43%-46.45M	-24.97%-187.32M	-22.94%-132.7M	-11.19%-89M	-16.61%-44.91M	-15.84%-149.89M	-12.61%-107.94M	-20.08%-80.04M
Administrative expenses	-5.85%-558.43M	-8.70%-376.62M	-3.60%-177.07M	-3.01%-662.7M	-14.39%-527.54M	-7.81%-346.47M	-7.54%-170.92M	-15.95%-643.32M	-18.67%-461.2M	-30.28%-321.38M
Research and development expenses	11.90%-172.1M	2.65%-124.69M	0.95%-63.91M	-11.48%-261.56M	-14.20%-195.34M	-15.89%-128.08M	-13.22%-64.52M	-10.76%-234.62M	-10.50%-171.06M	-18.80%-110.52M
Profit from asset sales	5,815.94%2.67M	25,346.07%1.49M	32,651.46%1.15M	----	282.55%45.22K	---5.9K	41.47%-3.54K	----	95.63%-24.77K	----
Revaluation surplus	-104.84%-34.41M	-118.58%-98.4M	-92.77%12.75M	----	76.46%710.39M	--529.76M	40.98%176.41M	----	-63.97%402.59M	----
-Changes in the fair value of other assets	-104.84%-34.41M	-118.58%-98.4M	-92.77%12.75M	----	76.46%710.39M	--529.76M	40.98%176.41M	----	-63.97%402.59M	----
Impairment and provision	-21.51%-55.1M	-21.18%-36.08M	11.22%-18.4M	-177.10%-68.1M	-0.74%-45.34M	-4.81%-29.78M	-76.90%-20.73M	-0.61%-24.58M	-152.89%-45.01M	-177.13%-28.41M
-Other impairment is provision	-21.51%-55.1M	-21.18%-36.08M	11.22%-18.4M	-177.10%-68.1M	-0.74%-45.34M	-4.81%-29.78M	-76.90%-20.73M	-0.61%-24.58M	-152.89%-45.01M	-177.13%-28.41M
Special items of operating profit	-5.47%130.76M	-18.28%88.09M	-61.93%11.78M	-4.57%863.91M	25.78%138.34M	-81.95%107.8M	-50.70%30.94M	-61.84%905.28M	-17.65%109.98M	-48.26%597.37M
Operating profit	-49.39%1.12B	-55.58%670.96M	-44.66%340.28M	-5.06%2.5B	17.21%2.21B	2.38%1.51B	-1.46%614.94M	-28.70%2.64B	-13.08%1.88B	-13.47%1.48B
Financing cost	-129.66%-31.37M	-81.71%16.11M	37.34%21.92M	-44.14%-119.9M	-11.06%105.76M	383.86%88.09M	-47.37%15.96M	-233.92%-83.18M	-32.28%118.91M	-290.77%-31.04M
Share of profits of associates	----	----	----	164.52%105.18M	----	----	----	177.13%39.76M	----	4,817.84%35.56M
Special items of earning before tax	-24.63%2.07M	452.48%3.02M	2.21%167.98K	----	-45.03%2.75M	--547.3K	-89.86%164.35K	----	201.12%4.99M	----
Earning before tax	-53.03%1.09B	-56.85%690.09M	-42.58%362.36M	-4.04%2.49B	15.38%2.31B	8.06%1.6B	-3.80%631.06M	-29.67%2.59B	-14.12%2.01B	-12.83%1.48B
Tax	35.83%-183.93M	30.64%-132.51M	20.63%-49.79M	-7.96%-338.61M	-22.61%-286.62M	-17.76%-191.06M	23.52%-62.74M	-7.10%-313.65M	-55.66%-233.77M	-56.70%-162.24M
After-tax profit from continuing operations	-55.46%903.14M	-60.40%557.58M	-45.00%312.57M	-5.68%2.15B	14.42%2.03B	6.87%1.41B	-0.98%568.33M	-32.84%2.28B	-18.92%1.77B	-17.35%1.32B
Earning after tax	-55.46%903.14M	-60.40%557.58M	-45.00%312.57M	-5.68%2.15B	14.42%2.03B	6.87%1.41B	-0.98%568.33M	-32.84%2.28B	-18.92%1.77B	-17.35%1.32B
Minority profit	-39.49%89.71M	227.70%64.73M	59,975.46%77.5M	-52.83%125.08M	-11.54%148.24M	-84.28%19.75M	-100.23%-129.43K	-48.76%265.17M	-58.59%167.58M	-62.42%125.62M
Profit attributable to shareholders	-56.72%813.43M	-64.50%492.85M	-58.65%235.07M	0.52%2.03B	17.13%1.88B	16.47%1.39B	9.65%568.46M	-29.98%2.02B	-9.90%1.6B	-5.39%1.19B
Basic earnings per share	-56.68%0.94	-64.60%0.57	-59.09%0.27	0.43%2.34	16.67%2.17	16.67%1.61	10.00%0.66	-29.82%2.33	-9.27%1.86	-4.83%1.38
Diluted earnings per share	-56.68%0.94	-64.60%0.57	-59.09%0.27	0.43%2.34	16.67%2.17	16.67%1.61	10.00%0.66	-29.61%2.33	-8.82%1.86	-4.17%1.38
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	IAS	CAS (2007)	CAS (2007)	CAS (2007)	IAS	CAS (2007)	IAS
Audit Opinions	--	--	--	Unqualified Opinion	--	--	--	Unqualified Opinion	--	--
Auditor	--	--	--	Lixin Certified Public Accountants (Special General Partnership), Hong Kong Lixin Dehao Certified Public Accountants Limited	--	--	--	Lixin Certified Public Accountants (Special General Partnership), Hong Kong Lixin Dehao Certified Public Accountants Limited	--	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

03347 TIGERMED

TIGERMED Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Analysis

Analyst Rating

Price Target